Pharming Group (NASDAQ:PHAR) Shares Gap Down – Should You Sell?

Pharming Group (NASDAQ:PHAR) shares gapped down prior to trading on Wednesday . The stock had previously closed at $9.93, but opened at $9.43. Pharming Group shares last traded at $9.52, with a volume of 864 shares traded.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Jefferies Financial Group assumed coverage on shares of Pharming Group in a report on Monday, December 9th. They issued a “buy” rating and a $14.00 target price for the company. Oppenheimer decreased their target price on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a report on Tuesday, December 17th.

Pharming Group Stock Performance

The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The firm has a market capitalization of $645.79 million, a price-to-earnings ratio of -36.62 and a beta of -0.08. The firm’s fifty day moving average is $8.76 and its 200 day moving average is $8.36.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its stake in shares of Pharming Group (NASDAQ:PHAR) by 16.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.